In a latest note to investors, a research analyst has provided a rating update for the Healthcare company, BriaCell Therapeutics (BCT – Research Report). The Healthcare company, BriaCell Therapeutics (TSX: BCT) has received a rating update from a Wall Street analyst today.
According to TipRanks.com, Bodnar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.5% and a 26.6% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Gracell Biotechnologies, and Olema Pharmaceuticals.
Currently, the analyst consensus on BriaCell Therapeutics is a Moderate Buy with an average price target of C$27.38.
Based on BriaCell Therapeutics’ latest earnings release for the quarter ending April 30, the company reported a quarterly net profit of C$0. In comparison, last year the company had a net profit of C$0.
BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.
The company’s shares closed last Tuesday at C$8.26.
Read More on TSE:BCT:
- BriaCell’s Phase 2 data makes H.C. Wainwright confident in pivotal study success
- BriaCell reports patient survival, clinical benefit in metastatic breast cancer
- BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
- BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders
- BriaCell accepts LOI from Weill Cornell Medicine on Bria-IMT trial plans
